Evidence map›Paper›PMID 39888240›Full record

ArticleEuropean journal of neurology2025

Small fiber neuropathy in the post-COVID condition and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical significance and diagnostic challenges.

Naiara Azcue, Sara Teijeira-Portas, Beatriz Tijero-Merino, Marian Acera, Tamara Fernández-Valle, Unai Ayala, Maitane Barrenechea, Ane Murueta-Goyena, Jose Vicente Lafuente, Adolfo Lopez de Munain and 5 more

Abstract read
In one paragraph

Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Naiara AzcueNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Spain.ORCID 0000-0002-6376-4951
Sara Teijeira-PortasNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Spain.
Beatriz Tijero-MerinoNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Spain.
Marian AceraNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Spain.
Tamara Fernández-ValleNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Spain.
Unai AyalaBiomedical Engineering Department, Faculty of Engineering (MU-ENG), Mondragon Unibertsitatea, Mondragón, Spain.
Maitane BarrenecheaBiomedical Engineering Department, Faculty of Engineering (MU-ENG), Mondragon Unibertsitatea, Mondragón, Spain.
Ane Murueta-GoyenaNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Spain.ORCID 0000-0002-9808-6943
Jose Vicente LafuenteDepartment of Neurosciences, University of the Basque Country UPV/EHU, Leioa, Spain.
Adolfo Lopez de MunainDepartment of Neurology, Donostia University Hospital-OSAKIDETZA, San Sebastián, Spain.
Guillermo Ruiz-IrastorzaAutoimmune Diseases Research Unit, Biobizkaia Health Research Institute, Barakaldo, Spain.
Daniel Martín-IglesiasAutoimmune Diseases Research Unit, Biobizkaia Health Research Institute, Barakaldo, Spain.
Iñigo GabilondoNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Spain.ORCID 0000-0001-6045-2840
Juan Carlos Gómez-EstebanNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Spain.
Rocio Del PinoNeurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Spain.ORCID 0000-0002-6612-4757

Funding

BIOEF through EITB maratoia BIOS21/COV/006health research projects from the Basque Government 2021111006Instituto de Salud Carlos III PI20/01076pre‑doctoral research grant from the Basque Government PRE_2023_2_0138
6 · The paper itself

Abstract

backgroundPatients with post-COVID condition (PCC) and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) experience symptoms potentially associated with small fiber neuropathy (SFN).

methodsA sample of 90 participants, comprising 30 PCC patients, 30 ME/CFS patients, and 30 healthy controls (HC), matched by sex and age, was assessed. Neuropathic, autonomic, and fatigue symptoms were measured with TaskForce Monitor, the Sudoscan, heat and cold evoked potentials, In Vivo Corneal Confocal Microscopy (IVCCM), and specialized questionaries.

resultsPCC and ME/CFS patients demonstrated significantly higher levels of autonomic symptoms (H = 39.89, p < 0.001), neuropathic symptoms (H = 48.94, p < 0.001), and fatigue (H = 49.29, p < 0.001) compared to HC. Quantitative sensory testing revealed significant differences in heat detection thresholds between PCC patients and HC (F = 4.82; p < 0.01). Regarding corneal small fiber tortuosity, there were statistically significant differences between patients and HC (F = 6.80; p < 0.01), indicating pathological responses in patients. Small fiber tortuosity in IVCCM was identified as the main discriminator between patients and HC (AUC = 0.720; p < 0.01).

conclusionPCC and ME/CFS patients demonstrated sensory SFN, as evidenced by impaired heat detection and increased tortuosity of small fibers in the central corneal subbasal plexus. The findings underscore the importance of a multimodal approach to comprehensively detect and characterize SFN. This study provides valuable scientific insights into the neuropathic manifestations associated with these conditions.

Indexed as

COVID-19Fatigue Syndrome, ChronicSmall Fiber NeuropathyAdultClinical RelevanceCorneaFemaleHumansMaleMiddle AgedPost-Acute COVID-19 SyndromeMyalgic Encephalomyelitis/Chronic Fatigue Syndromepost‐COVID conditionsmall fiber neuropathy

Identifiers

PMID39888240
PMCPMC11783232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.